Aldara

Aldara is a brand name of imiquimod topical, approved by the FDA in the following formulation(s):

ALDARA (imiquimod - cream; topical)

• 
  Manufacturer: MEDICIS
  
  Approval date: February 27, 1997
  
  Strength(s): 5% ^[RLD][AB]

Has a generic version of Aldara been approved?

A generic version of Aldara has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Aldara and have been approved by the FDA:

imiquimod cream; topical

• 
  Manufacturer: FOUGERA PHARMS
  
  Approval date: February 25, 2010
  
  Strength(s): 5% ^[AB]


• 
  Manufacturer: PERRIGO ISRAEL
  
  Approval date: September 7, 2010
  
  Strength(s): 5% ^[AB]


• 
  Manufacturer: TARO
  
  Approval date: April 15, 2011
  
  Strength(s): 5% ^[AB]


• 
  Manufacturer: TEVA PHARMS USA
  
  Approval date: April 18, 2011
  
  Strength(s): 5% ^[AB]


• 
  Manufacturer: TOLMAR
  
  Approval date: February 28, 2011
  
  Strength(s): 5% ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aldara. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Treatment for basal cell carcinoma
  Patent 7,696,159
  Issued: April 13, 2010
  Inventor(s): Owens; Mary L. & Fox; Terrance L. & Ginkel; Angela M.
  Assignee(s): Graceway Pharmaceuticals, LLC
  The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered.
  
  Patent expiration dates:
  
  
  • April 1, 2024
    
    ✓ 
    Patent use: WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
    ✓ 
    Drug substance
  
  
  
  • April 1, 2024
    
    ✓ 
    Patent use: TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
    ✓ 
    Drug substance
  
  
  
  • October 1, 2024
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Aldara Consumer Information (Drugs.com)
• Aldara Consumer Information (Wolters Kluwer)
• Aldara Consumer Information (Cerner Multum)
• Aldara Topical Advanced Consumer Information (Micromedex)
• Aldara AHFS DI Monographs (ASHP)
• Imiquimod Consumer Information (Wolters Kluwer)
• Imiquimod Cream Consumer Information (Wolters Kluwer)
• Imiquimod topical Consumer Information (Cerner Multum)
• Imiquimod Topical Advanced Consumer Information (Micromedex)
• Imiquimod AHFS DI Monographs (ASHP)